Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.

Chinese journal of cancer - 28 Oct 2016

Pang Xiufeng, Liu Mingyao

Abstract excerpt

The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years because of its inherent "undruggable" structure and undefined biological properties. As reported in the paper entitled "Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK" in Nature Communications, we performed a synthetic lethal screening with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Cyclin-Dependent Kinase Inhibitor p21
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Polo-Like Kinase 1

Share to Proto-Oncogene Proteins p21(ras)

Share to rho-Associated Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27793187
DOI: 10.1186/s40880-016-0154-7
PMCID: PMC5086049

Genes

KRAS
PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.PMID 27793187Read ↗

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.Semantic proximity Read ↗

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.Semantic proximity Read ↗

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Semantic proximity Read ↗

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read ↗

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.Semantic proximity Read ↗

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.Semantic proximity Read ↗

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system.Semantic proximity Read ↗

SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCERSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.